

Malaysia Results Review

22 February 2024

Sunway (SWB MK)

Highest-Ever Revenue Since Listing In 2011; BUY

- Maintain BUY with new TP of MYR3.53 (from MYR3.45), 30% upside, c.2% yield. Sunway's 4Q23 results beat expectations, driven by strong growth from key business segments. For 2024, management has set a higher sales target of MYR2.6bn (vs MYR2.44bn achieved in FY23). We like Sunway not only for its strategic exposure in Iskandar Malaysia and the upcoming listing of its healthcare unit, but also for Sunway Construction's (SCGB MK, BUY, TP: MYR3.34) promising job prospects. Our higher TP reflects our latest TP for SCGB.
- 4Q23 results. Property development, property investment, and construction divisions saw stronger revenue and EBIT, as billings were higher and occupancy and visitorship were much better during the quarter. JV income was higher in 3Q23 due to the recognition of MYR46.3m development profit as Parc Canberra in Singapore was completed. Meanwhile, share of net profit from the healthcare segment was lower QoQ, dragged by higher operating expenses, interest, and tax expenses. Note that Sunway Medical Centre Penang achieved breakeven at the PAT level during the quarter. A second interim dividend of 3.5 sen was declared, bringing full-year DPS to 5.5 sen (2022: 5.5 sen).
- Encouraging sales in 2023. New property sales reached MYR350m in 4Q23 vs MYR590m in 3Q23. Full-year property sales achieved MYR2.44bn (2022: MYR2.02bn), of which Singapore projects contributed MYR944m. Sales for Terra Hills and The Continuum in Singapore were slow, as the take-up rate for Terra Hills stayed at 39%, while The Continuum improved slightly to 37% from 33% in 3Q23, as tightening measures were announced in Apr 2023 after both projects were launched. However, projects in Johor saw encouraging sales. Bungalow units in Sunway Lenang Heights were 58% sold (launched in Nov 2023), while terrace homes in Sunway City Iskandar Puteri were 99% and 83% sold for Phase 1 and 2. Sunway plans to roll out MYR2.1bn worth of projects in 2024, including landed homes in Iskandar Puteri with a combined GDV of MYR345m, high-rise projects in Kelana Jaya (GDV: MYR455m), Bukit Jalil (GDV: MYR232m), and Taman Maluri (GDV: MYR566m).
- Forecast. Parc Central is expected to be completed in 1H24, and the accumulated progressive profits from this project stand at MYR108.9m. Unbilled sales and outstanding construction orderbook are at MYR4.06bn and MYR5.3bn vs MYR4.64bn and MYR5.8bn in 3Q23. In view of the strong earnings prospects from the healthcare, construction, and property development segments, we raise our FY24-25F earnings by 12-14%.
- ESG. Our SOP valuations include a 8% ESG premium.

Forecasts and Valuation	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26F
Total turnover (MYRm)	5,195	6,140	6,409	6,724	7,041
Recurring net profit (MYRm)	677	816	850	886	924
Recurring net profit growth (%)	155.1	20.6	4.1	4.2	4.3
Recurring EPS (MYR)	0.12	0.14	0.14	0.14	0.15
DPS (MYR)	0.06	0.05	0.06	0.06	0.07
Recurring P/E (x)	23.50	19.73	19.51	18.91	18.31
P/B (x)	1.27	1.16	1.15	1.13	1.10
Dividend Yield (%)	2.0	1.8	2.0	2.2	2.4
Return on average equity (%)	5.5	5.6	6.0	6.1	6.1
Net debt to equity (%)	52.3	43.4	41.7	39.3	35.6

Source: Company data, RHB

Property | Real Estate

Buy (Maintained)

Target Price (Return): MYR3.53 (30.2%)
Price (Market Cap): MYR2.71 (USD3,104m)
ESG score: 3.4 (out of 4)
Avg Daily Turnover (MYR/USD) 25.7m/5.46m


Analyst

Loong Kok Wen CFA +603 2302 8116 loong.kok.wen@rhbgroup.com



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	31.6	11.1	36.9	42.6	67.3
Relative	24.9	6.7	30.8	35.6	62.0
52-wk Price Ic	w/high (M	1YR)		1.53	-2.76



Source: Bloomberg

Overall ESG Score: 3.4 (out of 4)

E: EXCELLENT

Sunway City is a Green Building Index (GBI) certified township. The company managed to avoid 40,131 tonnes of CO2e from 2015-2019, and 1% of its electricity is from renewable sources (in 2019). Its main townships also have more than 40% open space, with greenscapes and bluescapes.

S: EXCELLENT

Sunway has made donations to aid the underserved communities in the B40 group, people with disabilities, youth, women, children and senior citizens. The Good Run in Oct 2019 managed to raise MYR275k to support medical treatment costs for cancer patients of the B40 group.

G: EXCELLENT

56% of board members are independent. Sunway has an inhouse investor relations team that is easily accessible, and holds investor meetings, embodying good transparency and disclosure practices.



Financial Exhibits

Asia				
Malaysia				
Property				
Sunway				
SWB MK				
Buy				

Valuation basis

30% discount to property RNAV, 10x P/E for trading/building material division, 20x EV/EBITDA for healthcare division, and 10% holding co discount

Key drivers

- i. New property sales;
- ii. Disposal of investment properties.

Key risks

i. Weaker-than-expected market conditions

Company Profile

A well-known developer in the Klang Valley. Its flagship project - Bandar Sunway is a well-established integrated township. The company has successfully transformed a mining land to a matured residential and commercial cluster

Financial summary (MYR)	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26F
Recurring EPS	0.12	0.14	0.14	0.14	0.15
EPS	0.12	0.12	0.14	0.14	0.15
DPS	0.06	0.05	0.06	0.06	0.07
BVPS	2.14	2.33	2.35	2.41	2.47
Return on average equity (%)	5.5	5.6	6.0	6.1	6.1
Return on average assets (%)	2.6	2.7	2.9	3.0	3.0
Valuation metrics	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26l
Recurring P/E (x)	23.50	19.73	19.51	18.91	18.31
P/B (x)	1.3	1.2	1.2	1.1	1.1
Dividend Yield (%)	2.0	1.8	2.0	2.2	2.4
EV/EBITDA (x)	33.67	29.48	29.11	26.63	25.73
Income statement (MYRm)	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26l
Total turnover	5,195	6,140	6,409	6,724	7,041
Gross profit	1,353	1,514	1,574	1,704	1,780
EBITDA	714	806	836	918	947
Depreciation and amortisation	(130)	(141)	(130)	(136)	(138)
Operating profit	583	664	706	783	809
Net interest	(14)	(68)	18	(8)	(2)
Pre-tax profit	920	993	1,148	1,247	1,301
Taxation	(167)	(138)	(207)	(262)	(273)
Reported net profit	677	738	850	886	924
Recurring net profit	677	816	850	886	924
Cash flow (MYRm)	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26l
Change in working capital	(661)	(449)	36	(155)	(156)
Cash flow from operations	145	426	959	771	793
Capex	(373)	(455)	(532)	(257)	(44)
Cash flow from investing activities	(929)	(159)	(388)	(27)	264
Dividends paid	(323)	(295)	(337)	(371)	(406)
Cash flow from financing activities	62	1,087	(431)	(464)	(498)
Cash at beginning of period	2,817	1,959	2,314	2,441	2,640
Net change in cash	(722)	1,353	140	280	559
Ending balance cash	2,095	3,312	2,454	2,721	3,199
Balance sheet (MYRm)	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26l
Total cash and equivalents	1,959	3.140		0.475	0.010
	1,959	3,140	3,266	3,465	3,860
Tangible fixed assets	1,959	17,980	3,266 18,382	18,503	
=				-,	18,410
Intangible assets	17,677	17,980	18,382	18,503	18,410 454
Intangible assets Total other assets	17,677 441 61 26,058	17,980 454	18,382 454	18,503 454	18,410 454 720 31,155
Intangible assets Total other assets Total assets	17,677 441 61	17,980 454 99	18,382 454 336 29,491 6,018	18,503 454 538	18,410 454 720 31,155
Intangible assets Total other assets Total assets	17,677 441 61 26,058	17,980 454 99 28,613	18,382 454 336 29,491	18,503 454 538 30,341	18,410 454 720 31,155 6,018
Intangible assets Total other assets Total assets Short-term debt	17,677 441 61 26,058 4,919	17,980 454 99 28,613 6,018	18,382 454 336 29,491 6,018	18,503 454 538 30,341 6,018	18,410 454 720 31,155 6,018 3,839
Intangible assets Total other assets Total assets Short-term debt Total long-term debt	17,677 441 61 26,058 4,919 4,137	17,980 454 99 28,613 6,018 3,633	18,382 454 336 29,491 6,018 3,758	18,503 454 538 30,341 6,018 3,822	18,410 454 720 31,155 6,018 3,839 14,315
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests	17,677 441 61 26,058 4,919 4,137 12,496	17,980 454 99 28,613 6,018 3,633 13,615	18,382 454 336 29,491 6,018 3,758 13,888	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335	18,410 454 720 31,155 6,018 3,839 14,315 15,401
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests	17,677 441 61 26,058 4,919 4,137 12,496 12,529	17,980 454 99 28,613 6,018 3,633 13,615 13,855	18,382 454 336 29,491 6,018 3,758 13,888 14,368	18,503 454 538 30,341 6,018 3,822 14,124 14,883	18,410 454 720 31,155 6,018 3,839 14,315 15,401
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity Total liabilities & equity	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562 26,058	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998 28,613	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603 29,491	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218 30,341	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity Total liabilities & equity Key metrics Revenue growth (%)	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562 26,058 Dec-22	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998 28,613	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603 29,491 Dec-24F	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218 30,341 Dec-25F	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155 Dec-26l
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurring net profit growth (%)	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562 26,058 Dec-22 39,9	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998 28,613 Dec-23 18.2	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603 29,491 Dec-24F 4,4	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218 30,341 Dec-25F 4,9	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155 Dec-26l
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity Total liabilities & equity	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562 26,058 Dec-22 39,9 155.1	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998 28,613 Dec-23 18.2 20.6	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603 29,491 Dec-24F 4,4 4,1	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218 30,341 Dec-25F 4,9 4,2	3,860 18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155 Dec-26f 4.7 4.3 3.3 25.3
Intangible assets Total other assets Total assets Short-term debt Total long-term debt Total liabilities Shareholders' equity Minority interests Total equity Total liabilities & equity Key metrics Revenue growth (%) Recurring net profit growth (%) Recurrent EPS growth (%)	17,677 441 61 26,058 4,919 4,137 12,496 12,529 1,033 13,562 26,058 Dec-22 39,9 155.1 155.1	17,980 454 99 28,613 6,018 3,633 13,615 13,855 1,143 14,998 28,613 Dec-23 18.2 20.6 19.1	18,382 454 336 29,491 6,018 3,758 13,888 14,368 1,235 15,603 29,491 Dec-24F 4,4 4,1 1,1	18,503 454 538 30,341 6,018 3,822 14,124 14,883 1,335 16,218 30,341 Dec-25F 4,9 4,2 3,2	18,410 454 720 31,155 6,018 3,839 14,315 15,401 1,439 16,840 31,155 Dec-26l 4,7 4,3 3,3

Source: Company data, RHB



Results At A Glance

Figure 1: Quarterly results

FYE Dec (MYR mil)	4Q22	3Q23	4Q23	Q ₀ Q (%)	YoY (%)	FY22	FY23	YOY (%)	Comments
Turnover	1,531.6	1,539.1	1,868.8	21.4	22.0	5,195.0	6,139.8	18.2	
Prop dev	442.7	309.5	499.4	61.3	12.8	1,165.3	1,418.8	21.8	Revenue was higher QoQ due to higher sales and progress billings from new and ongoing local projects
Prop invt	230.7	232.8	256.3	10.1	11.1	690.0	898.4	30.2	Revenue was stronger due to year-end festive season and hence higher visitorship and occupancy.
Construction	291.0	424.0	532.8	25.7	83.1	1,281.6	1,688.9	31.8	The higher sequential revenue was mainly due to higher progress billings from local projects.
Trading & Manufacturing	233.5	242.6	260.1	7.2	11.4	902.1	954.6	5.8	
Quarry	123.4	148.8	124.8	(16.1)	1.1	406.2	446.3	9.9	
Investment holdings	6.5	12.9	6.6	n.m.	n.m.	19.3	23.7	22.6	
Others	204.0	168.5	188.9	12.1	(7.4)	730.5	709.2	(2.9)	
EBIT	212.7	119.1	291.9	145.0	37.2	583.4	664.4	13.9	
EDITAL : (0/)	40.00/	7 70/	45.00			44.00/	40.00/		
EBIT Margin (%)	13.9%	7.7%	15.6%	40040	(4.65)	11.2%	10.8%	(0.7)	
Prop dev	65.9	2.8	55.1	1834.2	(16.5)	120.1	116.8	(2.7)	The lower EBIT YoY was mainly due to slower billings during the in stage of construction for a few local projects.
Prop invt	67.7	42.5	124.4	192.8	83.8	200.4	240.8	20.1	EBIT was boosted by net fair value gains from revaluation of investment properties of MYR67.9m in 4Q23.
Construction	67.4	57.4	81.9	42.7	21.5	190.1	231.8	21.9	
Trading & Manufacturing	10.9	14.4	13.9	(4.1)	27.3	46.6	51.6	10.8	
Quarry	5.8	10.3	8.6	(15.9)	48.2	16.0	28.5	78.1	
Investment holdings	(34.1)	(9.2)	(24.3)	n.m.	(28.8)	(88.4)	(64.7)	(26.8)	
Others	29.1	0.9	32.3	3560.8	11.1	98.6	59.5	(39.6)	
Exceptional items	10.1	0.0	78.3	n.m.	n.m.	17.6	75.2	n.m.	
Finance cost	(0.6)	(28.0)	(21.5)	(23.5)	3495.0	(14.5)	(68.2)	370.9	
Asso & jv	81.8	156.7	80.0	(49.0)	(2.3)	350.8	397.0	13.2	The higher JV income was attributed to the recognition of development profit of MYR46.3m as Parc Canberra in Singapore w completed in 3Q23.
Other Income	0.0	0.0	0.0	n.m.	n.m.	0.0	0.0	0.0	
Pretax profit	293.9	247.8	350.4	41.4	19.2	919.8	993.2	8.0	
PBT margin (%)	19.2%	16.1%	18.8%			17.7%	16.2%		
Тах	(73.7)	(40.5)	(33.1)	(18.4)	(55.1)	(167.0)	(137.7)	(17.5)	
Tax (%)	25.1%	16.4%	9.4%			18.2%	13.9%		
PAT	220.2	207.3	317.3	53.1	44.1	752.8	855.6	13.6	
MI	(17.2)	(27.0)	(51.4)	-	n.m.	(53.8)	(117.8)	119.0	
Net profit	203.0	180.3	265.9	47.5	31.0	699.1	737.8	5.5	Alexander
Core net profit	213.1	180.3	344.2	90.9	61.5	716.7	816.2	13.9	Above expectations.
Net margin (%)	13.9	11.7	18.4						
EPS (sen)	3.5	2.6	4.4			8.1	8.1		
NTA (RM)	2.14	2.19	2.15			2.14	2.14		
DPS (sen)	3.5	0.0	3.5			2.0	2.0		
EBIT margin:									
Prop dev	14.9%	0.9%	11.0%			10.3%	10.3%		
Prop invt	29.3%	18.3%	48.5%			29.0%	29.0%		
Construction	23.2%	13.5%	15.4%			14.8%	14.8%		
Trading & Manufacturing	4.7%	6.0%	5.3%			5.2%	5.2%		
Quarry	4.7%	6.9%	6.9%			3.9%	3.9%		
Investment holdings	n.m.	n.m.	n.m.			n.m.	n.m.		
Others	14.2%	0.5%	17.1%			13.5%	13.5%		

Source: Company data, RHB



Figure 2: RNAV estimate

		D t t	D t . t		
Developments		Remaining Landbank (acre)	Remaining GDV (MYR m)	Effective stake	NPV @ 10%
Selangor/KL		,/	,,		. 0 _0/0
Sunway Damansara		13.19	938.30	60%	66.0
Sunway South Quay		32.90	2,486.70	100%	279.7
Sunway Monterez		4.40	38.00	60%	2.8
Sunway Semenyih		523.11	728.59	70%	46.8
Sunway Cheras		2.92	4.50	100%	0.4
Sunway Duta		3.16	120.00	60%	6.3
Sunway Resort City		7.7	660	100%	84.3
Sunway Living Space (Sri Hartamas)		5.09	850.00	100%	84.5
Sunway Velocity 2		1.01	80.00	60%	3.4
Sunway Velocity 3		5.50	1,200.00	60%	65.8
New land in Cochrane		5.52	1,150.00	100%	109.6
Sunway Tower KL 1		0.92	240.00	100%	20.0
Sunway Termuning Mont Putra, Pawang		31.20 158.00	13.59 156.00	80% 100%	0.8 13.0
Mont Putra, Rawang Kelana Jaya		158.00 13.96	156.00 860.00	100% 100%	13.0 62.9
Kelana Jaya Sunway Belfield		1.65	000.00	100%	62.9
Jernih Residence, Kajang		2.44	264.00	60%	11.0
JSJ 1		14.80	1,400.00	100%	111.4
Mutiara Bukit Jalil		8.02	697.00	100%	52.9
Kuang land		245.00	2,000.00	100%	124.3
Dengkil (Emerald Tycoon)		61.23	813.90	100%	39.2
Perak					37.12
Sunway City Ipoh		324.1	3,746.38	96%	494.9
Penang					
Sunway Hills		80.70		100%	-
Sunway Wellesley, Bukit Mertajam		50.66	710.47	100%	56.7
Paya Terubong		19.79	1,500.00	100%	107.7
Sunway Tunas, Balik Pulau		9.37	20.60	100%	1.6
Sunway Betong, Balik Pulau		19.87	16.80	100%	1.3
5'pore					
Геrra Hills Pasir Panjang		4.79	2,873.00	30%	75.3
The Continuum Tanjong Katong		6.06	7,480.00	30%	112.0
Tengah Plantation Close 1		4.06	2,591.50	35%	67.7
Tengah Plantation Close 2		5.00	2,982.00	35%	71.1
ohor		.= = . =			=-
Bukit Lenang		30.48	850.00	80%	70.5
Medini Dondos		530.44	10,505.00	60%	471.2
Pendas Phina		1,071.47	18,000.00	100%	1,004.7
C hina Tanjin Phase 3		5.87	688.80	60%	26.0
ianjin r nase s		5.87	000.00	00%	26.0
Inbilled sales					391.0
OTAL		4,086.03	76,973.59		4,172.79
nvestment properties		Est. market value	Book value	Equity	Net surplus
		(MYR m)	(MYR m)	interest	(MYR m)
Monash University Campus		375.0	375.0	100%	0
Monash U Residence		465.0	465.0	100%	0
iunway Geo Tower		168.0	112.0	100%	56.0
unway Hotel Georgetown		60.0	37.6	100%	22.4
Sunway Hotel Phnom Penh		17.0	17.0	53%	0
Sunway Hotel Hanoi		1.0	1.0	100%	0
Sunway Giza		52.0	52.0	60%	0
Sunway Velocity Mall		1,900.0	908.5	59%	585.0
unway Velocity Hotel		112.0	112.0	39%	
unway Citrine Hub		42.0	42.0	60%	0.0
Sunway Geo Avenue		94.0	47.0	100%	47.0
Sunway Big Box retail hub		220.0	220.0	100%	0.0
Sunway Visio Tower		100.0	100.0	100%	0.0
unway V Office		160.0	160.0	100%	0.0
ubtotal					4,836.15
Shareholders' equity (ex cons. & healthcare)					12,872.54
Total					17,708.69
Discount to Property RNAV					30%
Discounted Property RNAV					12,396.08
Other divisions	Market value (MYR m)	Book value (MYR m)	Est. FY24 earnings (MYR m)	PE target (x)	Equity value surplus (MYR m)
0.9% Sunway REIT	2,437.3	1,479.0			958.30
4.6% Sunway Construction	2,357.8	844.0	a -		1,513.78
Others			85 Ext. EXC.4 EDITE: A	10	850.00
4% Sunway Healthcare			Est. FY24 EBITDA 451.4	EV/EBITDA (x) 20.1	Equity value 6,781.92
· / · · · · · · · · · · · · · · · · · ·			.52.1	20.1	3,. 31.72
Гotal					22,500.08
ESOS proceeds					151.21
Warrants conversion @ MYR1.56					1,044.44
Total RNAV					23,695.73
					10%
Holding company discount					
Holding company discount Discounted RNAV					21,326.16
					21,326.16 6,525.86
viscounted RNAV hare base (mil) incl. warrants & ICPS ntrinsic value					6,525.86 3.27
Discounted RNAV					6,525.86

Source: RHB



Emissions And ESG

Trend	ana	lysis
-------	-----	-------

In FY22, Scope 1 emissions: Increased to 65,329 tonnes of CO2 equivalents (FY21: 53,765 tonnes of CO2 equivalents) and Scope 2 increased to 55,813tn (FY21: 42,307 tonnes of CO2 equivalents).


Emissions (tCO2e)	Dec-21	Dec-22	Dec-23
Scope 1	53,765	65,329	na
Scope 2	42,307	55,813	na
Scope 3	41,432	64,603	na
Total emissions	137,504	185,745	na

Source: Company data, RHB

Latest ESG-Related Developments

- Sunway is a constituent of FTSE4Good Bursa Malaysia Index.
- It aims to be carbon neutral by 2050.

ESG Rating History



Source: RHB

Recommendation Chart



Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2024-02-16	Buy	3.45	2.76
2024-01-07	Buy	3.00	2.22
2023-11-22	Buy	2.65	1.94
2023-09-28	Buy	2.67	1.99
2023-08-17	Buy	2.65	1.92
2023-01-12	Buy	2.06	1.61
2022-11-28	Buy	2.06	1.58
2022-08-24	Buy	2.06	1.66
2022-05-26	Buy	2.06	1.74
2021-11-25	Buy	2.06	1.68
2021-08-25	Buy	2.00	1.77
2021-07-13	Buy	2.02	1.71
2021-06-24	Buy	2.09	1.73
2021-05-26	Buy	1.92	1.66
2021-04-19	Buy	1.95	1.64

Source: RHB, Bloomberg

RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels
Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance snot a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the



Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable, Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Malaysia

Save as disclosed in the following link <u>RHB Research Conflict Disclosures – Feb 2024</u> and to the best of our knowledge, RHBIB hereby declares that:

1. RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.

- RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
 - *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- 4. RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Thailand

Save as disclosed in the following link <u>RHB Research Conflict Disclosures – Feb 2024</u> and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:

- RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHB Securities (Thailand) PCL is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- 1. *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesi:

Save as disclosed in the following link <u>RHB Research Conflict Disclosures – Feb 2024</u> and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report.
 - For the avoidance of doubt, interest in securities include the following:
 - Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*;
 - b) Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*.
 - c) Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - d) Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
 None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a
- None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.
**The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link <u>RHB Research Conflict Disclosures - Feb 2024</u> and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts
 do not have a financial interest (including a shareholding of 1% or more) in the
 issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- 4. RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any compensation
 or benefit in connection with the production of this research report or
 recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel:+603 9280 8888 Fax:+603 9200 2216

BANGKOK

RHB Securities (Thailand) PCL 10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500

Thailand Tel: +66 2088 9999 Fax:+66 2088 9799

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470